107 related articles for article (PubMed ID: 34320225)
1. Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive.
Mohseni YR; Saleem A; Tung SL; Dudreuilh C; Lang C; Peng Q; Volpe A; Adigbli G; Cross A; Hester J; Farzaneh F; Scotta C; Lechler RI; Issa F; Fruhwirth GO; Lombardi G
Eur J Immunol; 2021 Oct; 51(10):2522-2530. PubMed ID: 34320225
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
Boroughs AC; Larson RC; Choi BD; Bouffard AA; Riley LS; Schiferle E; Kulkarni AS; Cetrulo CL; Ting D; Blazar BR; Demehri S; Maus MV
JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30869654
[TBL] [Abstract][Full Text] [Related]
3. Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors.
Kremer J; Henschel P; Simon D; Riet T; Falk C; Hardtke-Wolenski M; Wedemeyer H; Noyan F; Jaeckel E
Front Immunol; 2022; 13():1005582. PubMed ID: 36618378
[TBL] [Abstract][Full Text] [Related]
4. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
Sauer T; Parikh K; Sharma S; Omer B; Sedloev D; Chen Q; Angenendt L; Schliemann C; Schmitt M; Müller-Tidow C; Gottschalk S; Rooney CM
Blood; 2021 Jul; 138(4):318-330. PubMed ID: 34323938
[TBL] [Abstract][Full Text] [Related]
5. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
6. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
7. IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.
Pang N; Shi J; Qin L; Chen A; Tang Y; Yang H; Huang Y; Wu Q; Li X; He B; Li T; Liang B; Zhang J; Cao B; Liu M; Feng Y; Ye X; Chen X; Wang L; Tian Y; Li H; Li J; Hu H; He J; Hu Y; Zhi C; Tang Z; Gong Y; Xu F; Xu L; Fan W; Zhao M; Chen D; Lian H; Yang L; Li P; Zhang Z
J Hematol Oncol; 2021 Jul; 14(1):118. PubMed ID: 34325726
[TBL] [Abstract][Full Text] [Related]
8. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis.
Guo Y; Xu B; Wu Z; Bo J; Tong C; Chen D; Wang J; Wang H; Wang Y; Han W
Eur J Immunol; 2021 Oct; 51(10):2513-2521. PubMed ID: 34323289
[TBL] [Abstract][Full Text] [Related]
9. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction.
Lamarthée B; Marchal A; Charbonnier S; Blein T; Leon J; Martin E; Rabaux L; Vogt K; Titeux M; Delville M; Vinçon H; Six E; Pallet N; Michonneau D; Anglicheau D; Legendre C; Taupin JL; Nemazanyy I; Sawitzki B; Latour S; Cavazzana M; André I; Zuber J
Nat Commun; 2021 Nov; 12(1):6446. PubMed ID: 34750385
[TBL] [Abstract][Full Text] [Related]
10. Antigen Specific Regulatory T Cells in Kidney Transplantation and Other Tolerance Settings.
Hu M; Rogers NM; Li J; Zhang GY; Wang YM; Shaw K; O'Connell PJ; Alexander SI
Front Immunol; 2021; 12():717594. PubMed ID: 34512640
[TBL] [Abstract][Full Text] [Related]
11. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1.
Liu B; Zhang W; Xia B; Jing S; Du Y; Zou F; Li R; Lu L; Chen S; Li Y; Hu Q; Lin Y; Zhang Y; He Z; Zhang X; Chen X; Peng T; Tang X; Cai W; Pan T; Li L; Zhang H
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375315
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells.
van Schalkwyk MCI; van der Stegen SJC; Bosshard-Carter L; Graves H; Papa S; Parente-Pereira AC; Farzaneh F; Fisher CD; Hope A; Adami A; Maher J
Cells; 2021 Jul; 10(7):. PubMed ID: 34359966
[TBL] [Abstract][Full Text] [Related]
14. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.
Biasco L; Izotova N; Rivat C; Ghorashian S; Richardson R; Guvenel A; Hough R; Wynn R; Popova B; Lopes A; Pule M; Thrasher AJ; Amrolia PJ
Nat Cancer; 2021 Jun; 2(6):629-642. PubMed ID: 34345830
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation.
Gabelli M; Marks DI; Sharplin K; Lazareva A; Mullanfiroze K; Farish S; Burridge S; Velangi M; Rampling D; Mozayani B; Chiesa R; Lucchini G; Samarasinghe S; Bartram J; Ghorashian S
Br J Haematol; 2021 Dec; 195(5):805-811. PubMed ID: 34322864
[No Abstract] [Full Text] [Related]
16. Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?
Safinia N; Vaikunthanathan T; Lechler RI; Sanchez-Fueyo A; Lombardi G
Eur J Immunol; 2021 Oct; 51(10):2373-2386. PubMed ID: 34375446
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T cell therapy for autoimmune disease.
Chung JB; Brudno JN; Borie D; Kochenderfer JN
Nat Rev Immunol; 2024 Jun; ():. PubMed ID: 38831163
[TBL] [Abstract][Full Text] [Related]
18. Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes.
Tuomela K; Levings MK
Diabetologia; 2024 Apr; 67(4):611-622. PubMed ID: 38236408
[TBL] [Abstract][Full Text] [Related]
19. Promises and Pitfalls of Next-Generation Treg Adoptive Immunotherapy.
Christofi P; Pantazi C; Psatha N; Sakellari I; Yannaki E; Papadopoulou A
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136421
[TBL] [Abstract][Full Text] [Related]
20. Unlocking the potential of Tregs: innovations in CAR technology.
Requejo Cier CJ; Valentini N; Lamarche C
Front Mol Biosci; 2023; 10():1267762. PubMed ID: 37900916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
